These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Efficacy of infliximab combined with surgery in the treatment of perianal fistulizing Crohn disease].
    Author: Yang BL, Lin Q, Chen HJ, Sun GD, Zhu P, Chen YQ, Gu YF.
    Journal: Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Apr; 16(4):323-7. PubMed ID: 23608791.
    Abstract:
    OBJECTIVE: To evaluate the efficacy of infliximab combined with surgery in the treatment of perianal fistulizing Crohn disease (CD). METHODS: Clinical data of 15 patients with perianal fistulizing CD receiving infliximab combined with surgery in the Affiliated Hospital of Nanjing University of Chinese Medicine from March 2010 to June 2011 were analyzed retrospectively. One week after operation, all the patients received infliximab infusion thrice at weeks 0, 2, and 6. Crohn disease activity index (CDAI), perianal Crohn disease activity index (PDAI), body mass index (BMI), routine blood test and endoscopy were evaluated at week 0, 14. Adverse reactions and healing time were recorded. RESULTS: At week 14, the response rate was 100% with 86.7% (13/15) complete responders. One patient had local improvement and one developed recurrent fistula. The mean healing time was 32.5 (20-45) d. Anorectal stenosis in 4 patients was significantly improved. At week 14, CDAI decreased to 114.0±90.3 from 230.5±97.5 after IFX treatment. PCDAI decreased to 2.8±3.2 from 9.9±3.4, and BMI increased to (21.5±3.0)kg/m(2) from (19.1±3.1)kg/m(2). C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), platelet and neutrophil were significantly decreased from baseline (all P<0.01). Intestinal mucosa healed completely in one patient. There were no serious adverse events except hypokalemia in one patient and severe infusion reaction in another. CONCLUSION: Infliximab combined with surgery is effective and safe for perianal fistulizing CD.
    [Abstract] [Full Text] [Related] [New Search]